Mitchell H Sokoloff1, Geoffrey F Joyce, Matthew Wise. 1. Section of Urologic Oncology, Division of Urology and Renal Transplantation, Department of Surgery, Oregon Health and Sciences University, 3181 Southwest Sam Jackson Park Road, Portland, OR 97239, USA.
Abstract
PURPOSE: We quantified the burden of testis cancer in the United States by identifying trends in its incidence, its treatment and the use of health care resources to estimate the economic impact of the disease. MATERIALS AND METHODS: The analytical methods used to generate these results were described previously. RESULTS: The overall incidence of testis cancer in the United States increased 46% between 1975 and 2001. During the same period the ratio of seminoma to nonseminoma increased and there were fewer men presenting with stage II and III tumors. Survival rates increased successively, attaining the current level of 95.9%. Treatment patterns changed and active surveillance increased as a primary treatment modality. Overall hospitalization rates for men with testis cancer decreased from 1.8/100,000 in 1994 and 1.4/100,000 in 2000. Care for white men shifted to the outpatient setting, which did not occur for black men. The estimated annual expenditure for testis cancer for privately insured individuals between ages 18 and 54 years was $6,236. National estimates of annual medical expenditures placed the total cost of treatment at $21.8 million in 2000, representing an increase of 10% over the total in 1994. Of men with testis cancer 16% missed work for treatment of the disease with an average of 8.4 total hours of work missed. CONCLUSIONS: The cost of testis cancer is estimated at almost $21.8 million annually. It appears to be increasing with time despite a shift to active surveillance treatments and less hospitalization.
PURPOSE: We quantified the burden of testis cancer in the United States by identifying trends in its incidence, its treatment and the use of health care resources to estimate the economic impact of the disease. MATERIALS AND METHODS: The analytical methods used to generate these results were described previously. RESULTS: The overall incidence of testis cancer in the United States increased 46% between 1975 and 2001. During the same period the ratio of seminoma to nonseminoma increased and there were fewer men presenting with stage II and III tumors. Survival rates increased successively, attaining the current level of 95.9%. Treatment patterns changed and active surveillance increased as a primary treatment modality. Overall hospitalization rates for men with testis cancer decreased from 1.8/100,000 in 1994 and 1.4/100,000 in 2000. Care for white men shifted to the outpatient setting, which did not occur for black men. The estimated annual expenditure for testis cancer for privately insured individuals between ages 18 and 54 years was $6,236. National estimates of annual medical expenditures placed the total cost of treatment at $21.8 million in 2000, representing an increase of 10% over the total in 1994. Of men with testis cancer 16% missed work for treatment of the disease with an average of 8.4 total hours of work missed. CONCLUSIONS: The cost of testis cancer is estimated at almost $21.8 million annually. It appears to be increasing with time despite a shift to active surveillance treatments and less hospitalization.
Authors: Charles B Simone; Kevin Kramer; William P O'Meara; Justin E Bekelman; Arnaud Belard; James McDonough; John O'Connell Journal: Int J Radiat Oncol Biol Phys Date: 2011-01-13 Impact factor: 7.038
Authors: Klaus-Peter Dieckmann; Hanna Richter-Simonsen; Magdalena Kulejewski; Raphael Ikogho; Henrik Zecha; Petra Anheuser; Uwe Pichlmeier; Hendrik Isbarn Journal: Urol Int Date: 2018-04-12 Impact factor: 2.089
Authors: Bernhard Holzner; Johannes M Giesinger; Jakob Pinggera; Stefan Zugal; Felix Schöpf; Anne S Oberguggenberger; Eva M Gamper; August Zabernigg; Barbara Weber; Gerhard Rumpold Journal: BMC Med Inform Decis Mak Date: 2012-11-09 Impact factor: 2.796
Authors: Bernhard Holzner; Fabio Efficace; Umberto Basso; Colin D Johnson; Neil K Aaronson; Juan I Arraras; Allan B Smith; Edward Chow; Anne S Oberguggenberger; Andrew Bottomley; Hannes Steiner; Luca Incrocci; Johannes M Giesinger Journal: Qual Life Res Date: 2012-03-10 Impact factor: 4.147
Authors: M Brait; L Maldonado; S Begum; M Loyo; D Wehle; F F Tavora; L H J Looijenga; J Kowalski; Z Zhang; E Rosenbaum; S Halachmi; G J Netto; M O Hoque Journal: Br J Cancer Date: 2011-11-08 Impact factor: 7.640
Authors: Phuong L Mai; Bingshu E Chen; Kathy Tucker; Michael Friedlander; Kelly-Anne Phillips; David Hogg; Michael A S Jewett; Istvan Bodrogi; Lajos Geczi; Edith Olah; Ketil Heimdal; Sophie D Fosså; Katherine L Nathanson; Larissa Korde; Douglas F Easton; Darshna Dudakia; Robert Huddart; Michael R Stratton; D Timothy Bishop; Elizabeth A Rapley; Mark H Greene Journal: Fam Cancer Date: 2009-07-17 Impact factor: 2.375
Authors: Phuong L Mai; Michael Friedlander; Kathy Tucker; Kelly-Anne Phillips; David Hogg; Michael A S Jewett; Radka Lohynska; Gedske Daugaard; Stéphane Richard; Catherine Bonaïti-Pellié; Axel Heidenreich; Peter Albers; Istvan Bodrogi; Lajos Geczi; Edith Olah; Peter A Daly; Parry Guilford; Sophie D Fosså; Ketil Heimdal; Ludmila Liubchenko; Sergei A Tjulandin; Hans Stoll; Walter Weber; Douglas F Easton; Darshna Dudakia; Robert Huddart; Michael R Stratton; Lawrence Einhorn; Larissa Korde; Katherine L Nathanson; D Timothy Bishop; Elizabeth A Rapley; Mark H Greene Journal: Urol Oncol Date: 2009-01-22 Impact factor: 3.498